Therapeutic approach and treatment regimens used in COVID-19 with angina pectoris.
DOI:
https://doi.org/10.62452/mx8nvq79Keywords:
Multidisciplinary therapy, thrombosis, corticosteroids, remdesivir, anticoagulants, personalized treatmentAbstract
The impact of SARS-CoV-2 transcended the respiratory landscape and significantly compromised cardiovascular function, generating inflammation, endothelial alterations, and thrombotic disorders that favored the onset or worsening of angina pectoris. Given this clinical reality, a cross-sectional and explanatory literature review was conducted to describe the therapeutic algorithms applied in patients with a simultaneous diagnosis of COVID-19 and angina pectoris. The analysis of the literature identified the need for individualized and carefully supervised approaches. It was observed that the antiviral drug Remdesivir displayed an adequate safety profile in this group of patients, while the indiscriminate use of corticosteroids could generate adverse effects, particularly at the renal level. Furthermore, it was found that anticoagulant and antiplatelet drugs were essential for preventing thrombotic events, although their administration required constant medical monitoring. The results showed that coordination between specialists in cardiology, infectious disease, and intensive care increased the effectiveness of therapeutic interventions. Consequently, it was concluded that the treatment of patients with COVID-19 and angina should be guided by a multidisciplinary and dynamic approach, prioritizing cardiovascular stability without compromising control of the viral infection. The findings highlighted the importance of optimizing drug selection and establishing flexible protocols that respond to individual clinical conditions, thus forming a basis for future integrated therapeutic guidelines.
Downloads
References
Álvarez, J., & Garcia-Moll, X. (2012). Caso clínico 2: paciente con angina crónica estable y varios factores de riesgo. Diagnóstico, estratificación pronóstica y tratamiento. Revista Española de Cardiología Suplementos, 12(4), 30–36. https://www.sciencedirect.com/science/article/pii/S1131358712700717
Benavides González, A. E., Rodríguez Macias, S. A., Astudillo Guanoluisa, C. M., Vera Espinoza, A. L., Lazo Jara, V. C., Yaguana Guajala, R. G., Tamayo Torres, M. M., García Muñoz, F. M., Astudillo Mancero, R. D., & Saltos Bonifaz, D. A. (2023). Guía esencial de medicina interna en el primer nivel de atención (Tomo 6). Cueva Editores.
Chukwunyere, U., Sehirli, A. O., & Abacioglu, N. (2021). COVID-19-related arrhythmias and the possible effects of ranolazine. Medical Hypotheses, 149, 110545. https://www.sciencedirect.com/science/article/pii/S0306987721000633
De la Torre Fonseca, L. M. (2020). Lesión miocárdica en el paciente con COVID-19. CorSalud (Revista de Enfermedades Cardiovasculares), 12(2), 171–183. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2078-71702020000200171
Driggin, E., Madhavan, M. V, Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., Brown, T. S., Der Nigoghossian, C., Zidar, D. A., & Haythe, J. (2020). Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. Journal of the American College of Cardiology, 75(18), 2352–2371. https://www.jacc.org/doi/abs/10.1016/j.jacc.2020.03.031
Eberhardt, N., Noval, M. G., Kaur, R., Amadori, L., Gildea, M., Sajja, S., Das, D., Cilhoroz, B., Stewart, O., & Fernandez, D. M. (2023). SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels. Nature Cardiovascular Research, 2(10), 899–916. https://www.nature.com/articles/s44161-023-00336-5
García Pérez, M. E. (2023). Caso clínico: proceso enfermero en un paciente postoperado de revascularización miocárdica por enfermedad trivascular [Tesis de Especialidad, Benemérita Universidad Autónoma de Puebla].
Lu, X., Zhang, L., Du, H., Zhang, J., Li, Y. Y., Qu, J., Zhang, W., Wang, Y., Bao, S., & Li, Y. (2020). SARS-CoV-2 infection in children. New England Journal of Medicine, 382(17), 1663–1665. https://www.nejm.org/doi/abs/10.1056/nejmc2005073
Pérez Abreu, M. R., Gomez Tejeda, J. J., & Dieguez Guach, R. A. (2020). Características clínico-epidemiológicas de la COVID-19. Revista Habanera de Ciencias Médicas, 19(2), 1–15. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=97798
Sancho Cando, E. D., Sancho Cando, M. A., Sancho Cando, A. V., Castellanos Carrasco, P. N., & Espinosa Zambrano, A. G. (2024). Isquemia Miocárdica, una Enfermedad con alta Mortalidad en Ecuador. Ciencia Latina: Revista Multidisciplinar, 8(5), 11575–11594. https://dialnet.unirioja.es/servlet/articulo?codigo=9848759
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Emily Mayerli Valencia-Mejía, María Ilusión Solís-Sánchez, Kerly Katalina Llerena-Meza (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish in Revista Metropolitana de Ciencias Aplicadas (REMCA), agree to the following terms:
1. Copyright
Authors retain unrestricted copyright to their work. Authors grant the journal the right of first publication. To this end, they assign the journal non-exclusive exploitation rights (reproduction, distribution, public communication, and transformation). Authors may enter into additional agreements for the non-exclusive distribution of the version of the work published in the journal, provided that acknowledgment of its initial publication in this journal is given.
© The authors.
2. License
The articles are published in the journal under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0). The terms can be found at: https://creativecommons.org/licenses/by-nc-sa/4.0/deed.en
This license allows:
- Sharing: Copying and redistributing the material in any medium or format.
- Adapting: Remixing, transforming, and building upon the material.
Under the following terms:
- Attribution: You must give appropriate credit, provide a link to the license, and indicate if any changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses or sponsors your use.
- NonCommercial: You may not use the material for commercial purposes.
- ShareAlike: If you remix, transform, or build upon the material, you must distribute your creation under the same license as the original work.
There are no additional restrictions. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
